fbpx

QQQ
+ 0.45
365.25
+ 0.12%
BTC/USD
-1870.61
41145.01
-4.35%
DIA
-0.27
339.67
-0.08%
SPY
-0.45
434.49
-0.1%
TLT
-0.13
151.15
-0.09%
GLD
+ 1.08
163.86
+ 0.65%

Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says

January 27, 2020 11:18 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says

Despite the controversy surrounding Biogen Inc's (NASDAQ:BIIB) Alzheimer's drug trial results and skepticism concerning its approvability, an analyst at Canaccord Genuity sounds upbeat.

The Analyst

Sumant Kulkarni upgraded Biogen from Hold to Buy and increased the price target from $305 to $360.

The Thesis

Even the aducanumab skeptics agree for a variety of reasons it has a decent shot at FDA approval, and this likelihood is not reflected in shares at current levels, Kulkarni said in a note. The analyst likes the opportunity Biogen presents heading into the regulatory saga on aducanumab.

Kulkarni clarified that the update isn't based on the merits or lack of thereof of the data or the longer-term implications of the eventual regulatory outcome on aducanumab.

"We cannot, however, underestimate investors' fear of missing out on the potential to get ahead of what might be an approval for the first ever disease-altering therapy for Alzheimer's, which simultaneously presents high unmet need and a large addressable market," the analyst wrote in the note.

Kulkarni believes investors don't appreciate Biogen's excluding-aducanumab pipeline much. The firm pointed out that there are several readouts coming through 2021.

The firm also said it likes the growth Biogen's biosimilars can drive over the longer term.

Kulkarni expects a fairly decent quarter when Biogen reports results on Thursday. Apart from the risk posed by aducanumab, the analyst sees other risks such as a ruling on Mylan NV's (NASDAQ:MYL) inter partes review on the Tecfidera patent in early February and competitive pressure for spinal muscular dystrophy drug Spinraza.

The Price Action

Biogen shares traded around $278.43 at time of publication.

Related Links:

9 Takeaways From The JPMorgan Healthcare Conference

Mike Khouw Highlights Unusual Options Activity In Biogen

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over read more
Analysts Predict Volatility In Biogen Shares Until March 2021

Analysts Predict Volatility In Biogen Shares Until March 2021

Wall Street analysts suggest that Biogen Inc (NASDAQ: BIIB) stock is about to see a significant selloff and could witness volatility until the Food and Drugs Ad read more
Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'

Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'

Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day. read more
Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company's Alzheimer's invest read more